Create a free account or log in.
4SC focuses on the development of novel small molecule drugs that target key mechanisms of cancer development, such as histone deacetylases (HDAC). Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life.
4SC's current product pipeline includes two programs in clinical development: resminostat and domatinostat.
4SC's goal is to advance its own drug development programs in order to increase the value of the Company as a whole through entering into valuable partnerships with pharmaceutical and biotechnology companies for the further development or commercialization of 4SC drug candidates, and/or the eventual marketing and sales of approved drugs in select territories, such as Europe.
46
Germany
Create a free account or log in to add companies to your watchlist, access more data, and chat directly with filings using our AI assistant (as shown!).
| Filing Information | Date & Language | Document Details | Actions |
|---|
No filings found matching your criteria
391200QOKN7LGVP0RQ86
Stifel Europe Bank AG
IKM
Sector
Health Care
Country
Spain
ISIN
Founded
1NKEMIA specializes in biotechnology research and innovation, offering advanced solutions for the pharmaceutical, chemical, and energy sectors.
2CUREX
Sector
Health Care
Country
Sweden
ISIN
SE0010468124
Founded
2cureX AB is a Danish biotech company specializing in functional precision medicine. It develops diagnostic tools to personalize cancer treatment.
ABERA
Sector
Health Care
Country
Sweden
ISIN
SE0015245097
Founded
Abera Bioscience is active in biotechnology. The company specializes in the development of vaccines based on its own internal developed …
ABNX
Sector
Health Care
Country
France
ISIN
FR0012616852
Founded
ABIONYX Pharma is a new-generation biotech company that aims to contribute to health through innovative therapies in indications where there …
ABLI
Sector
Health Care
Country
Sweden
ISIN
SE0002575340
Founded
2000
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when …
AB
Sector
Health Care
Country
France
ISIN
FR0010557264
Founded
2001
AB Science is a late-clinical-stage French company founded in 2001 by a team of scientists with the goal of developing …